Holen Sie sich die Stockscreener-App
17.22
3.10%
-0.55
Handel nachbörslich:
17.71
0.49
+2.85%
Schlusskurs vom Vortag:
$17.77
Offen:
$17.9
24-Stunden-Volumen:
129.24K
Relative Volume:
0.49
Marktkapitalisierung:
$781.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+9.68%
1M Leistung:
-9.70%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.02
$17.98
1-Wochen-Bereich:
$16.04
$18.50
52-Wochen-Spanne:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
17.22 | 806.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $121,672.60 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com Nigeria
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - MarketBeat
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 - Investing.com
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8%Still a Buy? - MarketBeat
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap UpHere's What Happened - MarketBeat
MapLight Therapeutics stock rises after accelerating clinical trial timelines By Investing.com - Investing.com Nigeria
MapLight Therapeutics stock rises after accelerating clinical trial timelines - Investing.com
MapLight Therapeutics accelerates timeline for Phase 2 trial results By Investing.com - Investing.com Nigeria
MapLight updates trial timelines and highlights CNS pipeline - TipRanks
MapLight Therapeutics accelerates timeline for Phase 2 trial results - Investing.com
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewswire Inc.
MapLight Therapeutics Expects Topline Results From Phase 2 Zephyr, Iris Trials in Q3 - marketscreener.com
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com Nigeria
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 7.9%Should You Sell? - MarketBeat
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to Hold Rating - Defense World
MapLight2025 Funding Rounds & List of Investors - Tracxn
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Es liegen keine Finanzdaten für Maplight Therapeutics Inc (MPLT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):